Skip to main content
LISATA THERAPEUTICS, INC. logo

LISATA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · LSTA ISIN · US1280583022 LEI · 5493002287F62M3EGQ04 US Manufacturing
Open in API
Filings indexed 1,093 across all filing types
Latest filing 2010-11-12 Interim / Quarterly Rep…
Country US United States of America
Listing US LSTA

About LISATA THERAPEUTICS, INC.

https://www.lisata.com/

Lisata Therapeutics is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for advanced solid tumors and other major diseases. The company's core technology is the proprietary CendR Platform®, designed to enhance the targeted, tissue-penetrating delivery of anti-cancer drugs to solid tumors. The platform also aims to target non-cancerous, immunosuppressive cells within the tumor microenvironment, seeking to improve the efficacy of a patient's immune system and immunotherapies in fighting cancer.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2010
Interim / Quarterly Report 9M 2010
2010-11-12 English
425 Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by NeoStem, Inc. It includes detailed financial statements of Progenitor Cell Therapy, LLC and Subsidiaries for multiple years and nine months ended September 30, 2010 and 2009, along with unaudited pro forma condensed combined financial statements. The filing discusses a merger agreement and updates financial information related to the acquired business. The presence of consolidated financial statements, audit reports, and pro forma financials within the 8-K indicates this is a current report providing financial updates related to a significant corporate event (merger). The document is not a full annual report (10-K) or quarterly report (10-Q), but a current report (8-K) with financial statements attached. The content fits best under the category of Regulatory Filings (RNS) as it is a current report filing with financial statements and merger-related disclosures, not a standalone audit report or annual report. Confidence is high due to the clear SEC form type and content.
2010-11-12 English
M&A Activity 2010
M&A Activity Classification · 100% confidence The document is a Form 8-K current report filed with the SEC, dated September 23, 2010, describing the entry into a material definitive agreement, specifically a merger agreement between NeoStem, Inc. and Progenitor Cell Therapy, LLC. The text details the terms of the merger, stock consideration, warrants, escrow arrangements, voting agreements, and management appointments post-merger. It includes detailed legal and financial terms related to the merger transaction but does not present financial statements or quarterly/yearly financial results. The document is not an annual or interim report, earnings release, or audit report. It is a regulatory filing reporting a significant corporate event (merger agreement) and related management information. Given the nature of the content and the form type (8-K), the most appropriate classification is M&A Activity (TAR), which covers announcements and documents related to merger proposals or takeover bids.
2010-09-23 English
425 Filing
M&A Activity Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated September 23, 2010, reporting the entry into a material definitive agreement, specifically a merger agreement between NeoStem, Inc. and Progenitor Cell Therapy, LLC. The text details the terms of the merger, stock considerations, voting agreements, and management appointments post-merger. It is a current report disclosing a significant corporate transaction rather than a full annual or quarterly financial report, earnings release, or other types of filings. The content aligns with announcements related to merger activity. According to the filing definitions, announcements and documents related to merger proposals or takeover bids fall under the category 'M&A Activity' with code TAR. Therefore, the appropriate classification is TAR with high confidence.
2010-09-23 English
Board/Management Information 2010
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is used for current reports on significant events. The content specifically announces the appointment of a new President and Managing Director for a subsidiary of the company. There is no financial data, earnings information, or detailed report content. The document includes a press release as an exhibit related to the appointment. This fits the category of Board/Management Information (MANG), as it announces a change in senior management. The document length is short and does not contain a full report or financial statements, so it is not an Annual Report or Interim Report. It is not a Regulatory Filing (RNS) fallback because the content clearly relates to management changes.
2010-09-08 English
FORM 4
Director's Dealing
2010-09-03 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.